Drug Profile

Research programme: cancer therapeutics - Merck & Co/Beryllium

Latest Information Update: 20 Jan 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ArQule; Beryllium
Developer Beryllium; Merck & Co
Class Small molecules
Mechanism of Action Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

16 Jan 2020 ArQule has been acquired and merged into Merck & Co
04 Nov 2016 ArQule and Beryllium jointly terminate the research and development agreement for programmed cell death protein and ligand inhibitors in Cancer (ArQule's form 10-K, filed in March 2017)
04 Nov 2016 Discontinued for Cancer in USA, as the agreement between the companies was terminated (ArQule's form 10-K, filed in March 2017)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com